News
-
-
-
COMMUNIQUÉ DE PRESSE
Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
Bausch Health Companies Inc. and Salix Pharmaceuticals win U.S. Court of Appeals case over XIFAXAN, affirming FDA approval delay until Oct. 2029. Statements from CEOs included -
-
-
COMMUNIQUÉ DE PRESSE
Le traitement de l’acné vulgaire par PrARAZLO(MC) (lotion de tazarotène, 0,045 %) est maintenant accessible aux patients couverts par PharmaCare, le régime d’assurance-médicaments public de la Colombie-Britannique
Bausch Health annonce l'accessibilité de la lotion ARAZLO aux patients de la Colombie-Britannique couverts par PharmaCare pour traiter l'acné. La technologie PRISMATREXMC favorise la tolérabilité du traitement -
COMMUNIQUÉ DE PRESSE
Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
Bausch Health, Canada Inc. announces availability of ARAZLO lotion for acne treatment through BC PharmaCare. ARAZLO offers unique formulation technology to enhance patient tolerability -
-
-
COMMUNIQUÉ DE PRESSE
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
Bausch Health Companies Inc. files lawsuit against Amneal Pharmaceuticals over XIFAXAN. Lawsuit follows FDA approval request for generic version of XIFAXAN. Bausch Health defends its XIFAXAN intellectual property